Pulmocide
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
44 Southampton Buildings, London, Greate...Phone Number
+44 2037639484Website
www.pulmocide.comRevenue
$7.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Pulmocide
Pulmocide is a unique biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients quality of life.Explore more
Pulmocide Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pulmocide your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Pulmocide had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Pulmocide
Website visits: Recent activity has been detected on your website
Check if Pulmocide has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Pulmocide has new funding data
Product Launch: Get notified when Pulmocide launches new products
Pulmocide, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Pulmocide is spiking on competitors!
Earning: See what the market has to say on Pulmocide recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Pulmocide as Masked Content
Find more new buyers
Compare Similar Companies to Pulmocide
Compare insights from companies similar to Pulmocide, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Pulmocide is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pulmocide is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pulmocide.
Pulmocide financials insights
Gather financial insights about Pulmocide, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series A
$27.5M
2017
Series B
$30.4M
2021
Series C
$92M
Pulmocide Tech Stack
A closer look at the technologies used by Pulmocide
See more technologies
Most Recent Scoops
New Hire
Executive Move
New Hire
Executive Move
Funding
Funding
Pulmocide News & Media
Pulmocide Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
LONDON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing inhaled opelconazole for patients suffering from serious acute and chronic respiratory diseases, today announced that Dan Burgess, Chief Executive Officer, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 from 5:00 p.m. – 5:25 p.m. PT in the Mission Bay Ballroom at The Westin in San Francisco.Pulmocide exits OPERA with evidence of antifungal efficacy - Fierce Biotech
The data suggest the candidate can prevent and eradicate infections without causing the problems associated with existing systemic therapies.Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole
Inhaled opelconazole observed to be generally well tolerated in this study as prophylaxis against pulmonary aspergillosis in lung transplant patientsPulmocide Announces Expansion of Management Team
LONDON, June 08, 2023 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced the appointments of Matt Dallas as its Chief Financial Officer and Ashish Sagrolikar as its Chief Commercial Officer.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pulmocide
Sign Up For FreeTo access detailed company insights
Pulmocide is a unique biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients quality of life.... Read More
